- Trials with a EudraCT protocol (44,407)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,407 result(s) found.
Displaying page 1,786 of 2,221.
| EudraCT Number: 2017-000319-18 | Sponsor Protocol Number: FW-UC-001 | Start Date*: 2018-02-07 | |||||||||||||||||||||
| Sponsor Name:FIRST WAVE BIOPHARMA INCORPORATION | |||||||||||||||||||||||
| Full Title: A phase I/IIa, open-label, three-stage, study to investigate the safety, the efficacy and the pharmacokinetics of Niclosamide enemas in subjects with active Ulcerative Proctitis or Ulcerative Proct... | |||||||||||||||||||||||
| Medical condition: Active ulcerative proctitis or ulcerative procto-sigmoiditis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Completed) DE (Prematurely Ended) AT (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2017-000322-35 | Sponsor Protocol Number: ACE-536-MF-001 | Start Date*: 2017-08-22 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With and With... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-000900-38 | Sponsor Protocol Number: FT01CARCIK | Start Date*: 2017-08-16 | |||||||||||
| Sponsor Name:FONDAZIONE TETTAMANTI M.DE MARCHI ONLUS | |||||||||||||
| Full Title: Open label, single arm, multicenter, dose escalation Phase I-IIa, trial to determine the safety of Allogeneic (donor derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 C... | |||||||||||||
| Medical condition: Relapsed or Refractory B cell Acute Lymphoblastic Leukemia after Haematopoietic Stem Cell Transplantation | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000990-35 | Sponsor Protocol Number: FARM12.PW7R_A6-DeprEpil | Start Date*: 2019-02-06 | |||||||||||
| Sponsor Name:DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA | |||||||||||||
| Full Title: EFFECTS OF ANTIDEPRESSANT TREATMENT WITH AGOMELATINE ON PATIENTS AFFECTED BY DEPRESSION AND EPILEPSY. A DOUBLE BLIND RANDOMIZED STUDY WITH ACTIVE CONTROL (ESCITALOPRAM) WITH PARALLEL GROUPS. | |||||||||||||
| Medical condition: Depression in patients affected by epilepsy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000873-35 | Sponsor Protocol Number: I4V-MC-JAHN | Start Date*: 2017-10-27 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis | |||||||||||||
| Medical condition: Atopic Dermatitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) CZ (Completed) HU (Completed) AT (Completed) ES (Ongoing) PL (Completed) FR (Completed) DK (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-000863-22 | Sponsor Protocol Number: 150681 | Start Date*: 2020-06-23 | |||||||||||
| Sponsor Name:Thomas Benfield | |||||||||||||
| Full Title: Safety and immunogenicity following meningococcal and pneumococcal immunization among adult people living with HIV A single center, non-blinded, randomized clinical trial | |||||||||||||
| Medical condition: Immunogenicity following pneumococcal and meningococcal vaccination among people living with HIV | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001418-27 | Sponsor Protocol Number: 20150168 | Start Date*: 2019-01-29 | |||||||||||
| Sponsor Name:Amgen Inc. | |||||||||||||
| Full Title: A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ABP 959 COMPARED WITH ECULIZUMAB IN ADULT SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) | |||||||||||||
| Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) NO (Completed) SI (Completed) IE (Completed) FI (Completed) SE (Completed) PT (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001548-36 | Sponsor Protocol Number: CO40016 | Start Date*: 2017-12-18 | ||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
| Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATI... | ||||||||||||||||||
| Medical condition: Locally advanced unresectable or metastatic triple-negative (estrogen receptor, progesterone receptor, and HER2 negative) breast cancer or locally advanced unresectable or metastatic hormone recept... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) PL (Completed) BE (Completed) FR (Completed) GR (Completed) SI (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2017-001746-10 | Sponsor Protocol Number: CSEG101A2301 | Start Date*: 2019-07-08 | ||||||||||||||||
| Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
| Full Title: A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adole... | ||||||||||||||||||
| Medical condition: Sickle Cell Disease with vaso-occlusive crisis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) GR (Completed) DE (Completed) FI (Trial now transitioned) ES (Ongoing) IT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-001994-18 | Sponsor Protocol Number: SYD985.002 | Start Date*: 2018-01-22 | |||||||||||
| Sponsor Name:Synthon Biopharmaceuticals BV | |||||||||||||
| Full Title: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician’s choice in patients with HER2-positive unresectable local... | |||||||||||||
| Medical condition: breast tumours | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Completed) NL (Completed) SE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002018-29 | Sponsor Protocol Number: A3921165 | Start Date*: 2020-12-09 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS | |||||||||||||
| Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) PL (Completed) DE (Completed) BE (Completed) IT (Completed) NL (Prematurely Ended) SE (Prematurely Ended) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002660-41 | Sponsor Protocol Number: NVG14L127 | Start Date*: 2019-04-29 | |||||||||||
| Sponsor Name:SANTEN SAS | |||||||||||||
| Full Title: A Phase IIIb, prospective, interventional, multicentre, three-year study to explore the long-term evolution of sign and symptoms, and occurrence of complications in Dry Eye Disease patients with se... | |||||||||||||
| Medical condition: DRY EYE DISEASE WITH SEVERE KERATITIS | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) PL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002322-20 | Sponsor Protocol Number: PA0010 | Start Date*: 2019-06-26 | |||||||||||
| Sponsor Name:UCB Biopharma SRL | |||||||||||||
| Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE ... | |||||||||||||
| Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) HU (Completed) ES (Completed) CZ (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002855-27 | Sponsor Protocol Number: IN-CA-311-3963/CTN299 | Start Date*: 2018-01-22 | |||||||||||
| Sponsor Name:UNIVERSITY HEALTH NETWORK | |||||||||||||
| Full Title: BonE health in ageING Women: Improvement or prevention of changes in Bone Mineral Density by Switching Antiretroviral Agents. Is there an optimal time to intervene? | |||||||||||||
| Medical condition: HIV infection and menopause | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002715-34 | Sponsor Protocol Number: ADN014 | Start Date*: 2018-01-30 | |||||||||||
| Sponsor Name:ADIENNE SA | |||||||||||||
| Full Title: A Phase I/II, open label, dose escalation study to investigate the pharmacokinetics, pharmacodynamics, safety and clinical activity of begelomab as an initial treatment of acute Graft-versus-Host D... | |||||||||||||
| Medical condition: Acute graft versus host disease after allogeneic hematopoietic stem cell transplantation or donor lymphocyte infusion | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003380-35 | Sponsor Protocol Number: EX9536-4388 | Start Date*: 2018-10-05 | ||||||||||||||||
| Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
| Full Title: SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity | ||||||||||||||||||
| Medical condition: Overweight Obesity | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BG (Completed) DK (Completed) FI (Completed) IE (Completed) PT (Completed) GB (GB - no longer in EU/EEA) LV (Completed) NL (Completed) CZ (Completed) HU (Completed) BE (Completed) AT (Completed) SE (Completed) HR (Completed) NO (Completed) IT (Completed) RO (Ongoing) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2017-003377-34 | Sponsor Protocol Number: 54767414ALL2005 | Start Date*: 2018-07-31 | |||||||||||||||||||||
| Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||||||||||||
| Full Title: An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age With Relapsed/Refractory Precursor B-cell o... | |||||||||||||||||||||||
| Medical condition: Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) FR (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Completed) Outside EU/EEA | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2017-003103-22 | Sponsor Protocol Number: BONSAI | Start Date*: 2017-11-28 | |||||||||||
| Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
| Full Title: Advanced or Metastatic Collecting ducts renal cell carcinoma | |||||||||||||
| Medical condition: Collecting Duct Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-003302-40 | Sponsor Protocol Number: WO40242 | Start Date*: 2018-04-10 | |||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
| Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCA... | |||||||||||||
| Medical condition: Locally advanced squamous cell carcinoma of the head and neck (SCCHN) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) BE (Completed) PT (Completed) HU (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003038-98 | Sponsor Protocol Number: BeyPro2 | Start Date*: 2017-11-23 | |||||||||||
| Sponsor Name:INTERGRUPPO MELANOMA ITALIANO | |||||||||||||
| Full Title: An evaluation of the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second-line treatment in patients with BRAFV600 mutation-positi... | |||||||||||||
| Medical condition: BRAFV600 mutation-positive metastatic melanoma in focal progression | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.